Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
about
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapyEvaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance TestingPrevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE studyVirologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencingTrends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational databaseFactors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South AfricaChallenges in initiating antiretroviral therapy in 2010.HIV-1 drug resistance and resistance testing.Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Frequency and distribution patterns of opportunistic infections associated with HIV/AIDS in Uganda.Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyComparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit.Data-intensive analysis of HIV mutations.Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, raResponse to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortGastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patientsEffects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsAntiretroviral therapies in women after single-dose nevirapine exposure.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE studyClinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study.Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesCost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real worldHIV protease inhibitors in gut barrier dysfunction and liver injury.Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.HIV protease inhibitors and obesity
P2860
Q24234853-B6C340A3-D51F-4698-8C92-F1C60916118CQ26750406-642DAB0A-1C85-45B6-BE45-787789D0F44CQ26784507-35C461F2-FB7C-458E-BD9E-AEF9EDEF5CCFQ27015850-49B340A2-289A-402F-AD64-09EBBC003373Q28271593-66D8DD8D-C6B8-4E73-ABD2-C14928DC5EF3Q28474221-66CD62B9-E3E5-4F29-8BEE-479C49C18DA6Q28480762-0E3FABAE-13A6-4777-84B5-81047977A6A6Q28542731-1B030397-5359-4FB4-AE2A-895E49E106E5Q28546698-16DDD865-717D-4B04-A7AC-C96B6939578CQ30227046-31F2BBFA-879B-4E46-8422-911B42B490B9Q30245693-716D0D3F-EEDB-40FF-8643-F944C01E0BA5Q30248286-52099581-C1DE-4429-86F9-AD2DD0E1F2FDQ30379957-BBA69B9B-7E14-40B1-94D6-0FB8958651CEQ30609066-CC0ACE75-57C8-4EF6-8B5D-098F43EF1233Q30815467-02EEC44B-DEB2-451D-8356-4A3FB414C4B4Q30829516-C3755125-F963-41E4-8384-2C460B462FB7Q30887525-A52CB0AA-D88B-44F1-A727-E7B0E5B5A8BFQ31074302-9EB8A573-B40A-4A24-8CAC-7430B5D864A3Q31110946-2BB3B15F-D199-4C86-B4B7-661B2FF4217FQ33578024-C2C601DF-FAD1-42D2-9C45-F8B246735B7EQ33760652-30BE0C44-CA33-4E00-BE81-4B6C9689E012Q33875048-A0CA3683-2F0D-4EFF-B401-2C6A0270ED76Q33918414-BCA64745-5519-4331-8647-CD4729F6098FQ34037355-91300A93-4974-4E7F-AD4A-707CB4310060Q34100037-4D67E63F-2F7A-4F1B-9103-366D1580CCE7Q34134900-D1AF5B3A-6C60-4D17-81EC-05CCFCFE9FFAQ34251223-5ECA2856-6361-4E8A-9757-E3CE19A079E1Q34280466-48C782C8-C38F-4E60-A2D0-EDE98515B733Q34363980-FED20FC7-61A3-4636-8523-0DFA7D61B17DQ34478840-C08391E9-143E-4965-B9C6-97E91EA0F7D5Q34481365-9D99D828-65AF-4A12-87FA-927BAA095D6EQ34542154-1FBC2775-786E-478F-AB42-3BFDAB19D4F2Q34546011-318217D2-B5B8-46E8-816F-6BBB5AAA12DDQ34563005-2F151B5B-D2C2-4569-AC6D-FF295F857B04Q34608823-C6B9F9C5-863C-47D9-8DF4-037293F97E38Q34617496-7F24F93D-5724-485C-B132-29B7BD5BE6D5Q34638302-C21E7FB5-D501-416D-92F3-B7C039D6B887Q34713094-71A36ED7-7AF4-4A6A-9193-B5342CBA0662Q34718314-2453C637-F414-4388-B087-A38A77F14BCDQ34792983-C6E01D14-6A7E-4A00-9D4A-CE66F620CF6B
P2860
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Once-daily atazanavir/ritonavi ...... y results of the CASTLE study.
@en
Once-daily atazanavir/ritonavi ...... y results of the CASTLE study.
@nl
type
label
Once-daily atazanavir/ritonavi ...... y results of the CASTLE study.
@en
Once-daily atazanavir/ritonavi ...... y results of the CASTLE study.
@nl
prefLabel
Once-daily atazanavir/ritonavi ...... y results of the CASTLE study.
@en
Once-daily atazanavir/ritonavi ...... y results of the CASTLE study.
@nl
P2093
P1433
P1476
Once-daily atazanavir/ritonavi ...... y results of the CASTLE study.
@en
P2093
Alexandra Thiry
CASTLE Study Team
Donnie McGrath
Graeme Moyle
Jaime Andrade-Villanueva
Jean-Michel Molina
Jorge Corral
Juan Echevarria
Lisa Percival
Marco Mancini
P304
P356
10.1016/S0140-6736(08)61081-8
P407
P577
2008-08-01T00:00:00Z